Used in targeted cancer therapy, particularly for hepatocellular carcinoma (HCC). Binds specifically to Glypican-3, a protein overexpressed in liver cancer cells, enabling immune-mediated destruction of tumor cells. Investigated in clinical trials for its role in antibody-dependent cellular cytotoxicity (ADCC) and as a potential diagnostic and therapeutic agent in solid tumors. Also explored for use in antibody-drug conjugates (ADCs) to deliver cytotoxic agents directly to GPC3-positive cancer cells, minimizing damage to healthy tissue.